[Modification of awake-sleep equilibrium by tabernanthine and some of its derivatives in the cat (author's transl)].
L Da Costa, I Sulklaper, R Naquet
Revue d'electroencephalographie et de neurophysiologie clinique 1980 DOI: 10.1016/s0370-4475(80)80027-x (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Experimental study Peer reviewed |
|---|---|
| Population | Chronically implanted cats |
| Interventions | Tabernanthine tartrate SAD 121 SAD 122 SAD 103 |
| Dose | Tabernanthine tartrate 2 mg/kg, SAD 121 3 mg/kg, SAD 122 2 mg/kg, SAD 103 7 mg/kg |
| Citations | 4 |
| Key findings | Tabernanthine tartrate and SAD 103 increase wakefulness and reduce slow wave and paradoxical sleep, while SAD 121 and SAD 122 have the opposite effect. |
Abstract
Intraperitoneal injections (ip.) of 4 alkaloid derivatives of ibogamine: tabernanthine tartrate (2 mg/kg), methoxy-16 ibogaine tartrate (SAD 121 - 3 mg/kg), methoxy-16 tabernanthine tartrate (SAD 122 - 2 mg/kg), and tabernanthine parachlorophenoxyacetate (SAD 103 - 7 mg/kg), were administered to chronically implanted cats. Tabernanthine tartrate and SAD 103 provoke an increase in wakefulness level, a reduction in the level of slow wave sleep (SOL) and transient blocking of paradoxical sleep (SP). The duration of this action is much longer with SAD 103 than with tabernanthine tartrate. The inverse is provoked by SAD 121 and SAD 122, with slight increases in SOL and SP levels. Problems raised by the waking effect of tabernanthine tartrate and SAD 103 are discussed in the context of the neurobiology of sleep.